ABSTRACT
INTRODUCTION
Almost one in five clinically recognized pregnancies miscarries spontaneously in the first trimester 1, 2 . On ultrasound, early miscarriage can be classified as (1) early fetal or embryonic loss, i.e. a gestational sac with a visible embryo without cardiac pulsations 3 , (2) anembryonic gestation, i.e. empty sac or sac with minimal embryonic debris without cardiac activity 3 , or (3) incomplete miscarriage, i.e. no visible gestational sac but ultrasound signs of retained products of conception 4 . In this work, early fetal or embryonic loss and anembryonic pregnancies are referred to as non-viable pregnancies. To ascertain non-viability in early pregnancy can be difficult, and new criteria of non-viable early pregnancy have been suggested [5] [6] [7] and incorporated into national guidelines [8] [9] [10] [11] [12] . Treatment of miscarriage should be individualized. Surgical evacuation and medical treatment are alternative methods to empty the uterus after miscarriage, but one can also await spontaneous emptying [13] [14] [15] . Medical and expectant management avoid the small risks of surgery and anesthesia 16, 17 . Misoprostol, a synthetic prostaglandin E1 analog, is the most studied medical treatment 13 , but should be avoided if there are contraindications to its use. The success rate of any treatment depends on the type of miscarriage (non-viable pregnancy or incomplete miscarriage), length of follow-up and definition of complete miscarriage. It may be underestimated if the follow-up period is very short. In incomplete miscarriage, the success rate of expectant management is similar to that of misoprostol treatment 4 . In non-viable pregnancies some studies report very low success of expectant management or treatment with placebo, but this may be explained by short follow-up 18, 19 . The primary aim of this randomized controlled trial was to compare expectant management with vaginal misoprostol treatment in early non-viable pregnancies with vaginal bleeding with regard to complete evacuation of the uterine cavity ≤ 10 days after randomization. Secondary aims were to compare the two methods with regard to complications and complete evacuation ≤ 17 days, ≤ 24 days and ≤ 31 days after randomization.
METHODS
This was a randomized controlled, open-label trial with individual randomization into two parallel groups 1:1, i.e. treatment with vaginal misoprostol or expectant management (ClinicalTrials.gov ID: NCT01033903). We deliberately chose an open label design because we wanted to study how these two management strategies work in clinical practice when both doctors and patients know which treatment is given. We did not aim to study the effect of misoprostol per se by comparing it with placebo treatment.
Patients were recruited from the emergency clinic of the Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö, Sweden. Local Ethical Committee approval was obtained (Dnr 83/2008) , and all participants gave written informed consent. Eligible were hemodynamically stable patients with vaginal spotting or bleeding in early pregnancy. Patients with heavy bleeding judged clinically to necessitate immediate surgical evacuation of the uterine cavity were not eligible.
Inclusion criteria were: ≥ 18 years old, ability to understand written and spoken Swedish, hemoglobin concentration (Hb) > 80 g/L, no contraindications to treatment with misoprostol, fulfilling ultrasound criteria for early non-viable pregnancy and fetal crown-rump length (CRL) ≤ 33 mm. Because of new recommendations for ultrasound criteria of early pregnancy failure [5] [6] [7] , we changed our ultrasound criteria of non-viability in 2014. Before 2014 the criteria of non-viability in our study were one of the following: (1) intrauterine gestational sac with a mean diameter > 16 mm with no embryonic pole 20 or (2) a gestational sac with an embryo with CRL ≥ 5 mm without cardiac pulsations 20 , or (3) if the above criteria were not fulfilled, a gestational sac with or without an embryo that showed no significant development at a repeat scan after 7 days 20 . After April 2014 the non-viability criteria in our study were one of the following: (1) intrauterine gestational sac with a mean diameter ≥ 25 mm with no embryonic pole or (2) a gestational sac with an embryo with CRL ≥ 7 mm without cardiac pulsations, or (3) if the above criteria were not fulfilled, a gestational sac with or without an embryo that showed no significant development at a repeat scan after 7 days 5, 6, 8, 9 . Since all patients were managed as outpatients we did not include patients with a fetus with CRL > 33 mm because of the risk of heavy bleeding at expulsion of the pregnancy.
Inclusion and follow-up of all patients recruited to the study were done by one of three doctors in the trial team. The flow of patients through the trial is shown in Figure 1 . Each patient was followed up with visits planned on day 10, 17, 24 and 31 after randomization, i.e. after initiation of treatment. As soon as complete expulsion of the pregnancy was achieved as assessed with transvaginal ultrasound, the patient was discharged with no more follow-up visits planned. Complete miscarriage was defined as no gestational sac in the uterine cavity and maximum anteroposterior diameter of the intracavitary contents < 15 mm as measured by transvaginal ultrasound on a midsagittal view.
Primary outcome was number of patients with complete miscarriage without dilatation and evacuation (D&E) within 10 days after randomization. Secondary outcomes were number of patients with complete miscarriage without D&E within 17, 24 and 31 days after randomization, number of patients with complications from randomization until 4 weeks after the uterine cavity was judged to be empty (with or without D&E) or, if expulsion did not occur within 31 days, 4 weeks after day 31. Secondary outcomes were also self-reported pain, use of analgesics, duration of vaginal bleeding and side effects (nausea, diarrhea, vomiting, headache and dizziness) until complete miscarriage or up to 31 days. The complications assessed were pelvic infection (endometritis/salpingitis), number of D&Es (emergency and others), blood transfusion and change in Hb concentration from inclusion until complete miscarriage. The number of patients treated with antibiotics (including those prescribed antibiotics), making unplanned visits, being hospitalized and taking sick-leave was also recorded. A diagnosis of endometritis was assigned to patients with low abdominal or pelvic pain and/or Follow-up day 17 (14) (15) (16) (17) (18) (19) (20) (21) (n = 29) Failed to appear (n = 1) Follow-up day 17 (14) (15) (16) (17) (18) (19) (20) (21) (n = 44) Failed to appear (n = 2)
D&E before first follow-up (n = 2) (Bleeding (n = 2)) D&E before first follow-up (n = Follow-up day 24 (22) (23) (24) (25) (26) (27) (28) (n = 34) Failed to appear (n = 2) Follow-up day 31 (30) (31) (32) (33) (34) (35) (36) (37) (n = 11)
Follow-up day 31 (30-37) (n = 17) Failed to appear (n = 5)
Retrospective review of patient records 4 weeks after complete miscarriage or after day 31 Analyzed (n = 94)
Retrospective review of patient records 4 weeks after complete miscarriage or after day 31 Analyzed (n = 90)
Complete miscarriage (n = 62)* Figure 1 Flow of patients through the trial. *One patient returned with vaginal bleeding after 2 months and retained pregnancy tissue was confirmed after surgical evacuation. †Did not fulfill inclusion criteria (viable pregnancy, n = 1; molar pregnancy, n = 1). ‡Did not fulfill inclusion criteria (scar pregnancy). §Underwent dilatation and evacuation (D&E) after 2, 6 and 8 weeks of additional observation (n = 3); complete miscarriage after 2 and 4 additional weeks (n = 2); treated with second dose of misoprostol at last trial follow-up and was judged to have complete miscarriage 1 week later (n = 1). ¶Underwent D&E after 1, 3, 3, 4, 6 and 8 weeks of additional observation (n = 6); complete miscarriage after 2 days, 1 week and 3 weeks (n = 3); did not return for follow-up until after 2 months when there was suspicion of arteriovenous shunts and was followed up with serum β-human chorionic gonadotropin which had normalized after 5 months (n = 1). 22 . Sample size calculation was based on the assumption of a 70% success rate (complete miscarriage within 10 days after randomization) in the misoprostol group and 50% success rate in the expectantly managed group [23] [24] [25] . To achieve 80% power with an alpha error of 0.05 the total required sample size was 93 patients in each group. To compensate for loss to follow-up, exclusions and incomplete data, we planned for 120 subjects in each group.
Randomization was computer-generated in blocks of six and was accomplished by an independent consultant at an off-site research service center. Allocation to misoprostol or expectant management was hidden in sealed opaque envelopes prepared and sequentially numbered by staff not involved in the trial. All enrolment was done by one of three clinicians in the trial team. After informed consent had been obtained, the consecutive envelope was opened and allocation was revealed to the clinician and the patient, i.e. neither the clinician nor the patient was blinded to treatment.
The day of randomization was defined as day 1. At inclusion, the patients were examined clinically and by ultrasound. The ultrasound equipment used was a Sequoia 512 (Acuson Inc., Mountain View, CA, USA) with a 4-7.5-MHz transvaginal transducer. Each patient was randomly allocated to expectant care or to treatment with a single vaginal dose of 800 μg misoprostol (four tablets at 200 μg) that was placed in the posterior vaginal fornix by the trial clinician. All patients got written information on the study and the management to which they had been assigned, along with the telephone number of the responsible trial clinician. A structured diary to record bleeding, pain, use of painkillers and side effects (nausea, vomiting, headache, dizziness and diarrhea) was handed out and participants were instructed to fill it in at home every day from day 1 until the miscarriage was complete or for at most 31 days, and to bring it to each scheduled follow-up visit. Participants self-rated bleeding and pain as none, mild, moderate or severe. All patients were offered a prescription of paracetamol with codeine to use in case of severe pain. On day 1, blood was drawn for analysis of Hb, human chorionic gonadotropin (hCG), progesterone and blood type. Rh-negative women received anti-D rhesus prophylaxis (1500 IU) within 72 h after inclusion. All participants were managed as outpatients.
The first follow-up visit was scheduled on day 10 as shown in the flowchart (Figure 1 ). On every follow-up visit, transvaginal ultrasonography and clinical examination were performed by the trial clinician, and Hb concentration was analyzed. If the gestational sac was still present, or if the uterine contents measured ≥ 15 mm in maximum anteroposterior diameter, the patient was scheduled for a subsequent follow-up visit after 7 days. If the miscarriage was considered to be complete no more visits were planned and the diaries were collected. If complete evacuation was not achieved on day 31, treatment was considered a failure and the patient was recommended D&E. Participants could ask for D&E at any time during the trial, if they did not want to await spontaneous emptying of the uterine cavity. The method of D&E was chosen by the doctor carrying out the procedure, the routine procedure being vacuum aspiration followed by blunt curettage without ultrasound guidance. Products of conception were not routinely analyzed histologically, and serum β-hCG levels were not checked after the miscarriage was considered complete.
Data were collected from the prospectively filled in research protocols, the patients' diaries and medical records. Prospectively collected data included information on results of clinical and ultrasound examinations at inclusion and follow-up visits and the planned management at each follow-up visit. Additional information regarding out-of-protocol visits, complications and interventions from inclusion (day 1) until 4 weeks after complete miscarriage (or 4 weeks after day 31 if miscarriage was not complete on day 31) was retrieved retrospectively from the patient records. According to the Swedish Medical Products Agency, assignment to treatment had to be noted in the patients' medical records, i.e. the person retrieving information from the patient records retrospectively could not be blinded to the assignment group.
Statistical analysis was performed using SPSS Statistics, version 21 (IBM Corp., Armonk, NY, USA). Analysis was by intention-to-treat. Main outcome measure was absolute risk difference with 95% confidence interval (CI). Differences in proportions were calculated with 95% CI including continuity correction using a calculator on www .vassarstats.net (©Richard Lowry). The somersd package in Stata version 14 (StataCorp LLC, College Station, TX, USA) was used to calculate differences in continuous variables with 95% CI.
The manuscript was prepared following the Consolidated Standards of Reporting Trials (CONSORT) guidelines 26 .
RESULTS
Between September 2008 and December 2015, 189 patients were recruited to the trial. Ninety-five patients were allocated to expectant management and 94 to treatment with misoprostol. Twenty-one patients (expectant group: 11, misoprostol group: 10) were recruited after the new ultrasound criteria of non-viable early pregnancy were adopted. Recruitment was slower than anticipated, and the number of patients recruited was lower than the planned 240 despite a prolonged recruitment period.
An overview of our main results are presented in Figure 1 . Two patients in the expectantly managed group withdrew consent shortly after enrolment and three were excluded because they were found not to fulfill our inclusion criteria at follow-up visits (viable pregnancy (n = 1), molar pregnancy (n = 1) and Cesarean scar pregnancy (n = 1); Appendix S1). Thus, 184 patients were analyzed with regard to treatment outcome, 90 receiving expectant management and 94 receiving misoprostol treatment.
Baseline characteristics of the study population are presented in Table 1 . Gestational age according to the last menstrual period ranged from 6 to 16 weeks. The distribution of the different types of miscarriage was similar in the two groups, but there was a slight imbalance between the groups with regard to parity, hCG levels and CRL. Outcome with regard to success rate and complications are presented in Table 2 and Figure 1 . The success rate was significantly higher in the misoprostol group: 62/94 (66.0%) vs 39/90 (43.3%) in the expectantly managed group had achieved complete miscarriage within 10 days (risk difference (RD) = 22.6%; 95% CI, 7.5-36.5%). However, one patient in the misoprostol group judged to have miscarried completely on her first follow-up visit returned with bleeding and dizziness after 2 months and underwent emergency D&E. Trophoblastic tissue was confirmed on histological examination. The cumulative rate of complete miscarriage (without D&E) within 17, 24 and 31 days was also higher in the misoprostol group than in the expectantly managed group. The success rate within 31 days was 81/94 (86.2%) vs 55/90 (61.1%) (RD = 25.1%; 95% CI, 11.6-37.5%).
D&E was significantly less common in the misoprostol group than in the expectantly managed group: 10/94 (10.6%) vs 31/90 (34.4%) (RD = −23.8%; 95% CI, −35.8 to −11.1%). The number of patients undergoing emergency D&E was similar, 2/94 (2.1%) in the misoprostol group vs 4/90 (4.4%) in the expectantly managed group (RD = −2.3%; 95% CI, −9.7 to 4.5%), but the number of patients undergoing D&E at their own request was much higher in the group receiving expectant management, 15/90 (16.7%) vs 3/94 (3.2%) (RD = 13.5%; 95% CI, 4.1-23.4%). Also, the number of patients undergoing D&E because of failed treatment was higher in the expectant group, although the difference was not statistically significant, 12/90 (13.3%) vs 5/94 (5.3%) (RD = 8.0%; 95% CI, −1.4 to 17.8%). The number of patients making unscheduled visits was also significantly higher in the expectantly managed group. One patient from each group had profuse blood loss and received a blood transfusion. No other major complications occurred in any of the groups. There was one case of repeat D&E because of retained products of conception in the misoprostol group. Two patients in the expectantly managed group underwent hysteroscopy, one because of retained products of conception after one D&E and one because of difficulties with evacuating the cavity at D&E due to a uterine septum.
Analysis of change in Hb concentration was not meaningful because different blood sampling methods were used at inclusion (venous) and follow-up (capillary). Capillary Hb concentration at last follow-up was similar in the two groups.
One hundred and sixty-eight patients completed and returned the form for self-report (diary) of bleeding, pain and side effects. The results are presented in Table 3 . Three patients (3.2%) in the misoprostol group and 13 patients (14.4%) in the expectantly managed group did not complete the diary and were excluded from the analysis of diary data. Duration of vaginal bleeding differed between the groups with 2.3 more days of bleeding in the expectantly managed group. Six patients in the expectantly managed group did not report any pain at all, while all patients in the misoprostol group reported at least some pain, and more patients in the misoprostol group took oral painkillers, 85/91 (93.4%) vs 59/77 (76.6%) (RD = 16.8%; 95% CI, 5.2-28.7%). Nausea, vomiting, headache, diarrhea and dizziness were equally common in the two groups. Data are given as n (%) or mean ± SD. *One patient judged to have had a complete miscarriage at first follow-up returned with vaginal bleeding after 2 months and underwent dilatation and evacuation (D&E); she is not included in total number of patients undergoing D&E, because she could not be classified both as having had a complete miscarriage and as failure of treatment. †17 missing values. ‡37 missing values. §From inclusion until 4 weeks after complete miscarriage or after 31 days if not complete miscarriage on day 31. Results are shown as n (%) or mean ± SD. *One patient in expectantly managed group reported nausea, dizziness and headache for 31 days, i.e. all days during study period.
DISCUSSION
This randomized controlled trial shows that treatment with vaginal misoprostol is more effective than is expectant management in evacuating the uterus in patients with early non-viable pregnancy and vaginal bleeding. Complete miscarriage was achieved within 10 days in 66% of the patients treated with misoprostol vs 43% of those managed expectantly. After 1 month, the success rate was 86% vs 61%. More patients in the expectantly managed group underwent D&E and made out-of-protocol visits, but more patients treated with misoprostol experienced pain and took painkillers. Major complications were rare in both groups. Our results are generalizable to patients similar to those included in this trial. They are not generalizable to patients with incomplete miscarriage (i.e. no gestational sac in the uterine cavity) or to patients without vaginal bleeding. Our study adds information to the existing literature, because our study population is well defined (only non-viable pregnancies with bleeding were included), and because D&E was not recommended before 31 days of observation. These are the strengths of our study. In many randomized trials comparing misoprostol treatment with placebo or expectant management, the study populations are less well defined than in our study (including patients both with and without bleeding or not stating if bleeding was present, or including both non-viable pregnancies and incomplete miscarriages without showing results separately for the two groups). In addition, in many trials, D&E was carried out after a very short period of observation, so that the chance of successful treatment with long observation cannot be evaluated properly. Results of published randomized trials comparing misoprostol treatment with expectant management or placebo are summarized in Table 4 18,19,23,25,27-31 . It is a limitation of our study that we did not attain the planned 240 patients. However, the number finally analyzed almost reached the number needed according to our sample size calculation. Difficulty with recruiting patients to randomized trials on management of early pregnancy failure is not unique to our study 25, 30, 32 . Our experience, in accordance with that of others, is that many patients have a strong preconceived treatment preference 32 . Some might find the open-label design of our trial a limitation. However, as explained above, we deliberately chose this design, because our aim was to compare two treatment regimens as they work in clinical practice when both doctors and patients know which treatment is given. It is a weakness that the person retrieving data retrospectively from patient records could not be blinded to the allocated treatment. However, the risk of bias is low, since most of the variables assessed retrospectively were well defined. It is also a limitation that we changed our inclusion criteria at the end of the recruitment period. We felt obliged to do so because new criteria for defining a non-viable early pregnancy on ultrasound examination were recommended [5] [6] [7] in several national guidelines [8] [9] [10] [11] [12] . Because chills and fever are known side effects of misoprostol treatment 33 , it is a limitation that the patients did not record these side effects in their diaries, meaning that we cannot provide reliable information on their prevalence. However, misoprostol-induced fever rarely lasts for more than 24 h after administration 33 , and neither prospectively recorded nor retrospectively retrieved information implied the occurrence of this complication. Another limitation is that, for logistic reasons, we are unable to report the total number of eligible patients during the study period.
There was a slight imbalance between the treatment groups in our trial, in that more women in the expectantly managed group were parous, had slightly higher hCG levels (while progesterone levels were very similar) and their fetuses had smaller CRL values. It is uncertain if these imbalances, explained by chance, affect the results of our trial. In a study by Schwärzler et al. 34 , hCG and progesterone levels seemed to be associated with complete miscarriage < 7 days in women with non-viable early pregnancy managed expectantly, while parity had no effect, and the effect of CRL was not examined.
We used the same or a similar definition of complete miscarriage as several other research teams, i.e. maximum sonographic anteroposterior diameter of the uterine cavity contents < 15 mm or ≤ 15 mm 23, 27, 29, 35 . This definition has been questioned 24, [36] [37] [38] [39] . It is likely that the success rate and the number of D&Es would have been different if we had used other criteria of success, e.g. absence of a gestational sac in the uterine cavity or cessation of vaginal bleeding.
Our results confirm those of others, that misoprostol treatment shortens the time to complete miscarriage in women with a non-viable early pregnancy 18, 19, 23, 25, 27, 31 (see Table 4 ), but they also show that expectant management is a viable alternative to medical treatment. Many women find expectant management highly attractive 24, 34, 40 . An important advantage of a 'watch and wait' approach is that it avoids the risk of terminating a normal pregnancy misdiagnosed as a failed one 41, 42 . One patient with a viable pregnancy was included in our trial, and randomization of viable pregnancies was also reported by Trinder et al. 25 . Our results indicate that approximately 50% of women with an early non-viable pregnancy who have started to bleed will miscarry spontaneously and completely within 2-3 weeks, but that waiting beyond this period is probably not worthwhile. Waiting beyond 2-3 weeks also seems futile in women treated with misoprostol. The number of unplanned visits and D&Es at patient's request was higher in women randomized to expectant management than to treatment with misoprostol, but the number is likely to be lower if women actively choose expectant management in accordance with their own preference. It is important to stress, that risks and benefits of all treatment options, including surgery (which was not evaluated in our trial but was in others 25, 30 ), should be considered and discussed with the patient to individualize treatment. The risks of surgical vacuum evacuation may be small in expert hands if performed under ultrasound guidance 43 but may be higher in patients with risk factors (e.g. previous Cesarean section). While prostaglandin treatment avoids surgical and anesthesiological risks, it should be used with caution in certain situations, e.g. in patients with cerebrovascular disease, coronary artery disease, or inflammatory bowel disease. When balancing advantages and disadvantages of different treatments against each other, the time from diagnosis to complete miscarriage, treatment-associated discomfort such as pain and limitation of conduct of life while awaiting complete miscarriage should be taken into account. To improve selection for expectant or medical treatment of non-viable early pregnancy, predictive factors for successful evacuation within a certain time should be sought. Moreover, the definition of complete miscarriage may need revision. It might be better to assess the appearance of the uterine cavity contents on ultrasound images than to rely on its anteroposterior diameter. Alternatively, the ultrasound definition of complete miscarriage could be replaced with a clinical definition, e.g. cessation of vaginal bleeding.
Tratamiento con misoprostol versus tratamiento expectante en mujeres con embarazos no viables tempranos y hemorragia vaginal: un ensayo controlado aleatorizado pragmático RESUMEN Objetivo Comparar el tratamiento vaginal con misoprostol con el tratamiento expectante en embarazos no viables tempranos con hemorragia vaginal respecto al vaciado completo de la cavidad uterina en los 10 días posteriores a la aleatorización.
Métodos Este fue un ensayo paralelo, aleatorizado, controlado y abierto, realizado en el Hospital Universitario de Skåne en Suecia. Las pacientes con embarazo anembriónico o con muerte del feto temprana (longitud céfalo-caudal ≤ 33 mm) y hemorragia vaginal se asignaron al azar, al tratamiento expectante o al tratamiento con una dosisúnica de 800 μg de misoprostol administrado por vía vaginal. Las pacientes fueron evaluadas clínicamente y por ecografía hasta que se logró el vaciado completo delútero (ausencia de saco gestacional en la cavidad uterina y máximo diámetro anteroposterior de los contenidos intracavitarios <15 mm, medido por ecografía vaginal en la proyección sagital media). Las visitas de seguimiento se planificaron a los 10, 17, 24 y 31 días. Se recomendó una dilatación y vaciado (DyV) cuando el aborto no se completó dentro de los 31 días, pero se realizó antes a solicitud de la paciente, o si hubo una excesiva hemorragia según lo estimado clínicamente. El análisis fue por intención de tratar. La medida de resultado principal fue el número de pacientes con aborto completo sin DyV ≤ 10 días.
Resultados Noventa y cuatro pacientes fueron aleatorizadas al tratamiento con misoprostol y 95 al tratamiento expectante. Después de la exclusión de tres pacientes y la retirada del consentimiento por parte de dos pacientes en el grupo de tratamiento expectante, se incluyeron 90 mujeres en este grupo. El aborto fue completo en ≤ 10 días en 62/94 (66%) de las pacientes en el grupo de misoprostol y en 39/90 (43%) de aquellas en el grupo de tratamiento expectante (diferencia de riesgo (DR) = 23%; IC 95%, 8-37%). A los 31 días, las cifras correspondientes fueron 81/94 (86%) y 55/90 (61%) (DR = 25%, IC 95%, 12-38%). Dos pacientes de cada grupo fueron sometidas a DyV de emergencia debido a una excesiva hemorragia y una de estas en cada grupo recibió una transfusión de sangre. El número de pacientes sometidas a DyV a petición propia fue mayor en el grupo con tratamiento expectante, 15/90 (17%) vs 3/94 (3%) en el grupo de misoprostol (DR = 14%; IC 95%, 4-23 %), al igual que el número de pacientes que realizaron visitas fuera del protocolo, 50/90 (56%) vs 27/94 (29%) (DR = 27%, IC 95%, 12-40%). En comparación con el grupo de tratamiento expectante, fue mayor el número de pacientes que experimentaron dolor en el grupo de misoprostol (71/77 (92%) vs 91/91 (100%), DR = 8%, IC 95%, 1-17%) y utilizaron analgésicos (59/77 (77%) vs 85/91 (93%), RD = 17%, IC 95%, 5-29%). No se reportó ningún efecto secundario importante en ninguno de los grupos.
Conclusiones En mujeres con embarazos no viables tempranos y hemorragia vaginal, el tratamiento con misoprostol es más efectivo que el tratamiento expectante para el vaciado completo delútero. Ambos métodos son seguros, pero el tratamiento con misoprostol está asociado con más dolor que el tratamiento expectante.
